Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orfadin 20 mg versus two 10 mg capsules bioequivalence study
NL-OMON39261Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nitisinone in Fumarylacetoacetase deficiency (HT1) (2 arms), sponsored by PRA Health Sciences. Primary endpoints: AUC72h and Cmax. Started Apr 2013; status: active, not recruiting.
02
Drugs
nitisinone
03
Conditions
Fumarylacetoacetase deficiency (HT1)
Beyond the preview
Go deeper on NL-OMON39261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39261.